MARKET

ACOR

ACOR

Acorda
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.040
-0.070
-6.31%
After Hours: 1.060 +0.02 +1.92% 16:46 03/27 EDT
OPEN
1.090
PREV CLOSE
1.110
HIGH
1.170
LOW
1.040
VOLUME
903.78K
TURNOVER
--
52 WEEK HIGH
13.53
52 WEEK LOW
0.7001
MARKET CAP
49.92M
P/E (TTM)
-0.1809
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ACOR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ACOR stock price target is 3.917 with a high estimate of 10.00 and a low estimate of 1.000.

EPS

ACOR News

More
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • What Makes Acorda (ACOR) a New Buy Stock
  • Zacks · 03/17 17:00
  • Why Is Acorda (ACOR) Down 54.7% Since Last Earnings Report?
  • Zacks · 03/14 16:30
  • The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
  • Benzinga · 03/12 11:37

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About ACOR

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
More

Webull offers kinds of Acorda Therapeutics Inc stock information, including NASDAQ:ACOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACOR stock news, and many more online research tools to help you make informed decisions.